This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

ACRODAT

Learn about the acromegaly-specific disease activity tool you can use to help monitor and optimise support for your acromegaly patients at every stage of their journey.

ACRODAT is a validated, web-based software medical device 


​​​​​​​Available as part of the commercial package offer for Somavert

Developed in collaboration with a panel of global acromegaly experts
​​​​​​​
No installation is required: ACRODAT is accessible on a majority of platforms including desktops, laptops and tablets

A guide to using ACRODAT 

Learn more about the development of ACRODAT, how to add and evaluate patients and more in the ACRODAT user guide

Download the guide

Request an ACRODAT demo

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Learn more

** This is an optional area where footnotes can live.

ACRODAT can be used to track acromegaly disease activity status from one appointment to the next

Monitors and highlights changes in five disease-specific parameters 

Card CTA

** This is an optional area where footnotes can live.

ACRODAT enables an ongoing holistic overview of each patient’s acromegaly

Categorises patients based on stable, mild or significant levels of disease activity

Card CTA

** This is an optional area where footnotes can live.

How it works 

A simple four step process to help track your patients progress

Following registration, each authorised user in your clinic can add a new patient or access existing patient data which is stored in encrypted form within searchable ACRODAT database 

Step 1: Adding patients 

Prior to each patient visit, you can generate a patient and visit-specific code. This enables the patient to log in to a patient-specific side of the site and complete a quality of life questionnaire for their upcoming visit. This can be done at home or in the waiting room beforehand. Alternatively, you can input QoL information in discussion with your patient during their consultation with you.

Step 2: Inviting patient to complete AcroQoL questionnaire 

At each patient visit, you will be asked to input brief information about clinical history and disease-specific parameters into the database.

Step 3: Data input 

Using a validated algorithm created in collaboration with acromegaly experts, ACRODAT calculates each patient’s current overall disease activity status. Patient data input over a period of time can be viewed graphically or exported as an Excel file.

Step 4: Assessing results and exporting data 

Example patient status graphs

Overall Status graph

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Card CTA

** This is an optional area where footnotes can live.

Symptoms graph

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Card CTA

** This is an optional area where footnotes can live.

IGF-I graph

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Card CTA

** This is an optional area where footnotes can live.

Quality of Life graph

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Card CTA

** This is an optional area where footnotes can live.

Why monitor?

Quality of life is commonly impaired in people with acromegaly, even after successful treatment1-3

Some patients are never asked about  the psychological impact of their condition


Acromegaly has a huge variety of symptoms and comorbidities, and hence there are equal number of key players involved in optimising care for patients with the condition1-5. However, the psychological aspect of dealing with acromegaly - together with the potential psychophysiological impact of pituitary hormone production imbalances caused by the condition itself - is something that can go overlooked 3-6

The importance of psychology

Dr Sue Jackson, Research Psychologist, University of Plymouth, discusses the importance of holistic support that considers the psychological impacts or acromegaly.

How ACRODAT facilitates a holistic approach to acromegaly care 

ACRODAT incorporates the AcroQOL questionnaire, a validated acromegaly-specific quality of life questionnaire.7 By capturing acromegaly-specific patient data on both the psychological and physical impact on quality of life for people living with the condition, ACRODAT provides a straightforward and systematic way for you to identify patients who may require further psychological support.

Explore more 

Contact us

To find out more about ACRODAT, supporting patients or ordering more starter kits

Contact us 

** This is an optional area where footnotes can live.

Acromegaly co-morbidities webinars

Watch and listen to our Rare Disease Insight series where expert speakers take a deep dive into the co-morbidities associated with acromegaly

Watch the webinars now

** This is an optional area where footnotes can live.


References:

1. Melmed S, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018;26:1.
2. Geraedts VJ, et al. Predictors of Quality of Life in acromegaly: no consensus on biochemical parameters. Frontiers in Endocrinol 2017;8(40):1–14.
3. Crespo I, et al. Update on quality of life in patients with acromegaly. Pituitary 2017;20(1):185–8.
4. Wayne Brown. Alone in my universe: Struggling with an orphan disease in an unsympathetic world. Indiana, United States. iUniverse. May 2011: 268.
5. Chanson P and Salenave S. Acromegaly. Orphanet J Rare Dis 2008;3:1–17.
6. Gurel MH, et al. Patient perspectives on the impact of acromegaly: results from individual and group interviews. Patient Preference and Adherence 2014;8:53–62.
7. Webb SM, Prieto L, BadiaX, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002;57:251–258.

PP-SOM-GBR-0953. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No